@misc{TschornKuhlmannRieckmannetal.2020,
  author    = {Tschorn, Mira and Kuhlmann, Stella Linnea and Rieckmann, Nina and Beer, Katja and Grosse, Laura and Arolt, Volker and Waltenberger, Johannes and Haverkamp, Wilhelm and M{\"u}ller-Nordhorn, Jacqueline and Hellweg, Rainer and Str{\"o}hle, Andreas},
  title     = {Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease},
  series = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  journal   = {Zweitver{\"o}ffentlichungen der Universit{\"a}t Potsdam : Humanwissenschaftliche Reihe},
  number    = {1},
  issn      = {1866-8364},
  doi       = {10.25932/publishup-55731},
  url       = {http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-557315},
  pages     = {11},
  year      = {2020},
  abstract  = {Objective: Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). Methods: The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. Results: Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. Conclusion: Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.},
  language  = {en}
}
@article{TschornKuhlmannRieckmannetal.2020,
  author    = {Tschorn, Mira and Kuhlmann, Stella Linnea and Rieckmann, Nina and Beer, Katja and Grosse, Laura and Arolt, Volker and Waltenberger, Johannes and Haverkamp, Wilhelm and M{\"u}ller-Nordhorn, Jacqueline and Hellweg, Rainer and Str{\"o}hle, Andreas},
  title     = {Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease},
  series = {Acta Neuropsychiatrica},
  volume    = {33},
  journal   = {Acta Neuropsychiatrica},
  number    = {1},
  publisher = {Cambridge Univ. Press},
  address   = {Cambridge},
  issn      = {1601-5215},
  doi       = {10.1017/neu.2020.31},
  pages     = {22 -- 30},
  year      = {2020},
  abstract  = {Objective: Depression and coronary heart disease (CHD) are highly comorbid conditions. Brain-derived neurotrophic factor (BDNF) plays an important role in cardiovascular processes. Depressed patients typically show decreased BDNF concentrations. We analysed the relationship between BDNF and depression in a sample of patients with CHD and additionally distinguished between cognitive-affective and somatic depression symptoms. We also investigated whether BDNF was associated with somatic comorbidity burden, acute coronary syndrome (ACS) or congestive heart failure (CHF). Methods: The following variables were assessed for 225 hospitalised patients with CHD: BDNF concentrations, depression [Patient Health Questionnaire-9 (PHQ-9)], somatic comorbidity (Charlson Comorbidity Index), CHF, ACS, platelet count, smoking status and antidepressant treatment. Results: Regression models revealed that BDNF was not associated with severity of depression. Although depressed patients (PHQ-9 score >7) had significantly lower BDNF concentrations compared to non-depressed patients (p = 0.04), this was not statistically significant after controlling for confounders (p = 0.15). Cognitive-affective symptoms and somatic comorbidity burden each closely missed a statistically significant association with BDNF concentrations (p = 0.08, p = 0.06, respectively). BDNF was reduced in patients with CHF (p = 0.02). There was no covariate-adjusted, significant association between BDNF and ACS. Conclusion: Serum BDNF concentrations are associated with cardiovascular dysfunction. Somatic comorbidities should be considered when investigating the relationship between depression and BDNF.},
  language  = {en}
}
@article{TschornRieckmannAroltetal.2019,
  author    = {Tschorn, Mira and Rieckmann, Nina and Arolt, Volker and Beer, Katja and Haverkamp, Wilhelm and Martus, Peter and Waltenberger, Johannes and M{\"u}ller-Nordhorn, Jacqueline and Str{\"o}hle, Andreas},
  title     = {Erkennungsg{\"u}te dreier deutschsprachiger Screeninginstrumente f{\"u}r Depression bei hospitalisierten Patienten mit koronarer Herzerkrankung},
  series = {Psychiatrische Praxis},
  volume    = {46},
  journal   = {Psychiatrische Praxis},
  number    = {1},
  publisher = {Thieme},
  address   = {Stuttgart},
  issn      = {0303-4259},
  doi       = {10.1055/s-0042-123434},
  pages     = {41 -- 48},
  year      = {2019},
  abstract  = {Ziel Vergleich der Erkennungsg{\"u}te von drei Depressions-Screeninginstrumenten bei Patienten mit koronarer Herzerkrankung (KHK). Methodik 1019 KHK-Patienten erhielten den Patient Health Questionnaire (PHQ-9 und PHQ-2) und die Hospital Anxiety and Depression Scale (HADS-D) sowie ein klinisches Interview (Composite International Diagnostic Interview) als Referenzstandard. Ergebnisse Bez{\"u}glich der Erkennungsg{\"u}te waren PHQ-9 und HADS-D dem PHQ-2 {\"u}berlegen. Optimale Cut-off-Werte waren 7 (PHQ-9 und HADS-D) und 2 (PHQ-2). Schlussfolgerung PHQ-9 und HADS-D haben eine vergleichbare Diskriminationsf{\"a}higkeit f{\"u}r depressive St{\"o}rungen bei KHK-Patienten.},
  language  = {de}
}